Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Firms Fear FDA Pill Size Guidance Helps Brands Stifle Competition

This article was originally published in The Tan Sheet

Executive Summary

FDA final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.

You may also be interested in...



ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit

Generics must be able to be administered without provider intervention or patient retraining, draft guidance says.

ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit

Generics must be able to be administered without provider intervention or patient retraining, draft guidance says.

FDA Rejects Generic Tablets Larger Than Brand Citing Safety And Efficacy Concerns

FDA denies ANDAs for one product because the generic tablet size is larger than the brand; the agency plans to release a draft guidance on generic equivalency to the reference listed drug in size, taste and smell.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS107867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel